Further to verify, if the clinical features and the molecular markers (specific for AA and GBM) correlate with the grading done by 16-gene signature, we have performed additional analysis on age, survival and molecular markers (CDKN2A/2B loss, EGFR amplification and p53 mutation). This evidence concerns the gene CDKN2A and glioblastoma.